{"ticker": {"uuid": "4c3e5d46-b7a8-42bb-8646-2cad990cb4d5", "symbol": "TRVI", "name": "Trevi Therapeutics  Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target", "summary": "BMO Capital has initiated coverage on Trevi Therapeutics (TRVI) with an Outperform rating and set a price target of $36. This announcement follows B. Riley's recent adjustment of Trevi Therapeutics' price target to $31 from $21, maintaining a Buy rating. Trevi Therapeutics is a c", "url": "https://www.marketscreener.com/news/bmo-capital-initiates-trevi-therapeutics-at-outperform-with-36-price-target-ce7f51d8d98ef02c", "source_name": "marketscreener.com", "published_at": "2026-07-21T11:12:05", "published_display": "21 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMO initiates Trevi Therapeutics stock at Outperform, $36 target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOZkdKYkhON2phZWtKVllfcVJJbjl6dEk1dE5UWmNCdUR4YWhKTnpsbFJINm1YZkMySE4xRTktc3gtM1NHWEthVUNfUlM4TUJZdGgtZlR4QVZCU2MyZWhDTE1VX1V1R1NHenJFQmNIcjlIb04ta3RqRF8zcHktT3pqckk5Z3FyYkRPRVZJYW42cHBJZmtkbUNDS1lfbllOY2FDMFZCRWJlYjFWS0FfZTNnMFJuQlU2a1FYMlIwTnZMaWYzejlkNFBKTmlB?oc=5", "source_name": "Investing.com", "published_at": "2026-07-20T21:48:00+00:00", "published_display": "20 Jul 2026 21:48", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1% - Here's Why", "summary": "Trevi Therapeutics (NASDAQ:TRVI) saw its shares drop 5.1% on Monday, trading as low as $18.03 with below-average volume, following a previous close of $19.07. This decline occurred despite several analysts recently raising price targets and maintaining a \"Moderate Buy\" consensus ", "url": "https://www.marketbeat.com/instant-alerts/trevi-therapeutics-nasdaqtrvi-shares-down-51-heres-why-2026-07-20/", "source_name": "MarketBeat", "published_at": "2026-07-20T18:09:43", "published_display": "20 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Financial Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNUjBtTzJBbENaWi0zdFRoSWpET0JWZFNrSC1NQlU1Wi1BMHRoWDljLWNjdG1wVkhTdGo0OWd4QkQ4WW9IQmpMd3FjbkQzZmNmU3hwSjI2akw0ZE9oRXlyYVBtc2V0N1JweHlkbU5ZVmFQVkNnZWhEQXNsMUJDbWtzTjZTOUxWczBqM2Q1R0w4MjJpb0tEM1VTb3RJUnlLSWcyOFVaU1Iwcm5YVE9pQ0doem9fZm9KaHA4ZzZyZ0RuWXFaeTdweF9wbnBvemh5LWd4eDNYM0lHdVVNQQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-20T13:50:48+00:00", "published_display": "20 Jul 2026 13:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Adjusts Trevi Therapeutics Price Target to $31 From $21, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/b-riley-adjusts-trevi-therapeutics-120905218.html", "source_name": "MT Newswires", "published_at": "2026-07-20T12:09:05+00:00", "published_display": "20 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOb2tfRFpCSXdTR2ZhUUhRcGxDRllWY1RrS0tsMUNTMllXUXozOXc5NkdpNkxhaTdXVlctVFNJMkFlZXFabTlYUXpYUjg3WHhoQ2hyeGZfYi1xZmhBbkRDSDI0d09FbkxLQ0xyWGdiQXBnTHV3eG00dkYxRmwyMDRPbXZ6eUZ3cW5QT3dqVjRYX1lET2ViZm5iZlNMdllZUlB4TUhGMUhaLVk2cEJ0SmxnUUZMWG9QWVdLcjB6UWRTdVZ0ZjFqOGZuX3U0cmZmZnFNbTdFdUkxTmhRREpGU3dfdGFUNVQxMGZCM1Fma0FfOVFQUFFFTUtXdXc4a2xfcTQycEduZDVOenZJMUtQLXpJQnlCOE0tQ3VLMGlGdWNfcUxrQUk5cklRaXlUR2U?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-20T12:08:00+00:00", "published_display": "20 Jul 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics stock price target raised to $24 by H.C. Wainwright", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPdmFSeG9yb09OQmFSZmJpMEIzUmUteGZsVUN6Rjh1LXpLaWU0ZldnRU53X0p2ZDJtOENkaGQ4bnNvVHI4SXJLSEs3MmZXNVB0QU54WmlnZXQyVGtFNmliNTg4bDUwZFA4YmllLUdpTngybVg3WDlvUkdBb0ZMTVNiU3pYTUYzX2FQb3RBWERxYk9jYXRRbHR4N2tiV2s4aDd1MHluekhxaTdCakpMM1p2azNiXzFqM0RuTGFVTDluM1V6SHFvbXc?oc=5", "source_name": "Investing.com", "published_at": "2026-07-20T11:40:57+00:00", "published_display": "20 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price", "summary": "HC Wainwright has raised its price target for Trevi Therapeutics (NASDAQ:TRVI) to $24 from $21, maintaining a buy rating and suggesting a potential upside of 25.85%. Despite a recent quarterly EPS miss, other analysts also hold a generally positive outlook, contributing to a cons", "url": "https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-positive-forecast-for-trevi-therapeutics-nasdaqtrvi-stock-price-2026-07-20/", "source_name": "MarketBeat", "published_at": "2026-07-20T11:41:30", "published_display": "20 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "_TRVI Surges As Trevi Therapeutics Draws Fresh Bullish Momentum", "summary": "Trevi Therapeutics Inc. (TRVI) stock surged over 11% following optimistic investor response to clinical progress and a non-deal roadshow. Despite being a development-stage biotech with negative profitability and cash burn, the company boasts a strong balance sheet with substantia", "url": "https://www.timothysykes.com/news/trevitherapeuticsinc-trvi-news-2026_07_19-2/", "source_name": "www.timothysykes.com", "published_at": "2026-07-19T14:07:00", "published_display": "19 Jul 2026 14:07", "sentiment": "positive", "sentiment_pct": 75, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRVI Surges As Trevi Therapeutics Draws Aggressive Buyers", "summary": "Trevi Therapeutics (TRVI) stock surged by 11.6% due to strong investor optimism driven by promising clinical progress and aggressive accumulation by traders. Despite being a clinical-stage biotech with no product revenue and negative fundamentals, TRVI boasts exceptional liquidit", "url": "https://timothysykes.com/news/trevitherapeuticsinc-trvi-news-2026_07_19/", "source_name": "timothysykes.com", "published_at": "2026-07-19T10:08:00", "published_display": "19 Jul 2026 10:08", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics (TRVI) Is Up 6.9% After Haduvio Cough Data And New ILD Trial Plan - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-19T08:31:28+00:00", "published_display": "19 Jul 2026 08:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Stock Jumps As Momentum Traders Pile In", "summary": "Trevi Therapeutics Inc. (TRVI) stock has experienced an 11.6% jump, driven by positive drug trial news and aggressive buying interest from momentum traders. Despite being a clinical-stage biotech with negative profitability, the company maintains strong liquidity with $172M in ca", "url": "https://timothysykes.com/news/trevitherapeuticsinc-trvi-news-2026_07_18-2/", "source_name": "timothysykes.com", "published_at": "2026-07-18T15:09:54", "published_display": "18 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRVI Jumps As Trevi Therapeutics Extends Rally On Heavy Interest", "summary": "Trevi Therapeutics (TRVI) stock experienced an 11.6% surge following promising clinical data, generating significant investor and trading interest. The company is set to meet institutional investors in London, contributing to positive sentiment. Despite being a clinical-stage bio", "url": "https://stockstotrade.com/news/trevitherapeuticsinc-trvi-news-2026_07_18-2/", "source_name": "StocksToTrade", "published_at": "2026-07-18T11:38:00", "published_display": "18 Jul 2026 11:38", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRVI Jumps As Trevi Therapeutics Extends Bullish Run", "summary": "Trevi Therapeutics Inc. (TRVI) stock has jumped by 11.6% due to optimism over its latest clinical trial developments and a Cantor Fitzgerald-hosted non-deal roadshow in London. Despite strong liquidity and no debt, the company is pre-revenue with negative returns and significant ", "url": "https://timothysykes.com/news/trevitherapeuticsinc-trvi-news-2026_07_18/", "source_name": "timothysykes.com", "published_at": "2026-07-18T10:08:00", "published_display": "18 Jul 2026 10:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High - Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOT0J0aTY0UXcteDdWTU1DUHdoZzNzbzlUbFlwRDVKUVRZc2Y3SkV2dmRId0FMNmxvbFIwUUs2alNVX2g2di1tVVJpRXBiLUgtQW16bVhKTTNYQ3RkeHBwZ19DWVVqQ1dhb2w5TlNwV1ViV1k5ZnZYbHZMSjlYVERSdGRZTW9pdGtUMWpMRUxfZnRoMS1pcU1vbmo0Rng0RVNoTl9Rb0tFRjZDVkFsS0VGMU0yMjg?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-18T08:34:57+00:00", "published_display": "18 Jul 2026 08:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Trevi Therapeutics (TRVI) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxObmxkaWs5NFFka183TkNaa1VUdHFaZEhjVE5jbzliRjN0SHk5eDdJRTE0Ql92aVFjQmx3eEVNUm1OOXVRa1NBSmNHVGFTSlFacXZILTVnbVpsZnZiOTlkdmdLU1F6TmV0aGhleWFSaUNyLW9rRDB0N2Z2N3JlNzdMU045TVpDYVM2T3d6NQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T18:37:00+00:00", "published_display": "17 Jul 2026 18:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics (TRVI) Stock May Be Overvalued Despite Its 5 Year Surge", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-17T18:35:32+00:00", "published_display": "17 Jul 2026 18:35", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market", "summary": "Trevi Therapeutics (TRVI) saw its share prices rise by 9.85% after its CEO and Chief Development Officer presented strong clinical trial results for Haduvio, their treatment candidate for chronic cough, at a European conference. Haduvio, an extended-release formulation of nalbuph", "url": "https://finance.yahoo.com/healthcare/articles/trevi-therapeutics-trvi-soars-haduvio-022042519.html", "source_name": "Market source", "published_at": "2026-07-17T19:20:00", "published_display": "17 Jul 2026 19:20", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi climbs as GSK drops chronic cough therapy (TRVI:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQdUo3eHpCV3dJZl9jZEhBODloS3g5YTNZZERWMDE1V1Jhck12em1VMjVFZ2FVSUxHd3NrNUV0allNckhnejdyOV9kNWZ0cXZaUXE0V0tialc0Z0djelpNUkVDaWlEcERRdDdkdEdXYnRYRE81T0t5Qy16d1U0aUJfWVNTODBTdmxSM3c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-17T18:04:33+00:00", "published_display": "17 Jul 2026 18:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRVI Stock Firms Up As Haduvio Story Hits Center Stage", "summary": "Trevi Therapeutics Inc. (TRVI) stock is showing a strong upturn, driven by optimism surrounding its Haduvio clinical development and an aggressive outreach campaign. Management is engaging in a London non-deal roadshow hosted by Cantor Fitzgerald and participating in multiple ind", "url": "https://stockstotrade.com/news/trevi-therapeutics-inc-trvi-news-2026_07_17/", "source_name": "StocksToTrade", "published_at": "2026-07-17T17:40:36", "published_display": "17 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading Volume - Should You Buy?", "summary": "Trevi Therapeutics (NASDAQ:TRVI) experienced a significant surge in trading volume and stock price, with shares jumping to $20.12 on Friday. Analysts maintain a generally positive outlook, reiterating \"buy\" ratings and setting an average price target of $22.67, despite the compan", "url": "https://www.marketbeat.com/instant-alerts/trevi-therapeutics-nasdaqtrvi-sees-strong-trading-volume-should-you-buy-2026-07-17/", "source_name": "MarketBeat", "published_at": "2026-07-17T16:40:35", "published_display": "17 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Stock Traders Buy Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI)", "summary": "Trevi Therapeutics (NASDAQ:TRVI) experienced a significant surge in call option trading, with 13,996 call options bought on Wednesday, a 1,258% increase from the typical volume. This occurred despite a 0.43% share price drop to $17.48. Analysts maintain a \"Buy\" consensus rating w", "url": "https://www.marketbeat.com/instant-alerts/stock-traders-buy-large-volume-of-trevi-therapeutics-call-options-nasdaqtrvi-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T17:48:44", "published_display": "15 Jul 2026 17:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candriam S.C.A. Purchases Shares of 773,620 Trevi Therapeutics, Inc. $TRVI", "summary": "Candriam S.C.A. acquired a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the first quarter, purchasing 773,620 shares valued at approximately $9.23 million. This investment represents about 0.60% of Trevi Therapeutics' total ownership. Other institutional investor", "url": "https://www.marketbeat.com/instant-alerts/filing-candriam-sca-purchases-shares-of-773620-trevi-therapeutics-inc-trvi-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T08:11:12", "published_display": "13 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "SG Americas Securities LLC Decreases Stock Position in Trevi Therapeutics, Inc. $TRVI", "summary": "SG Americas Securities LLC significantly reduced its stake in Trevi Therapeutics (NASDAQ:TRVI) by 77.5% in the first quarter, selling 96,511 shares and leaving them with 28,051 shares. Despite this reduction, institutional investors collectively hold a strong position, with 95.76", "url": "https://www.marketbeat.com/instant-alerts/filing-sg-americas-securities-llc-decreases-stock-position-in-trevi-therapeutics-inc-trvi-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T09:09:37", "published_display": "10 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRVi stock stays tied to Trevi Therapeutics' clinical outlook", "summary": "Trevi Therapeutics (TRVI) stock performance is predominantly influenced by its clinical pipeline progress, especially its oral therapies for chronic cough and fibrosis-related conditions. The company's valuation relies heavily on successful study readouts and its ability to trans", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/trvi-stock-stays-tied-to-trevi-therapeutics-clinical-outlook/69733563", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T18:17:00", "published_display": "09 Jul 2026 18:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Trevi Therapeutics, Inc. \u2013 NASDAQ:TRVI", "summary": "This article displays information regarding the forward price-to-earnings ratio for Trevi Therapeutics, Inc. (NASDAQ: TRVI). It serves as a financial data point within a trading platform interface for investors and analysts, without providing further analysis or discussion. The a", "url": "https://www.tradingview.com/symbols/NASDAQ-TRVI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T23:41:58", "published_display": "08 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics stock hits all-time high at 19.33 USD", "summary": "Trevi Therapeutics (TRVI) stock recently reached an all-time high of $19.33, reflecting a significant 226.05% increase over the past year and strong investor confidence. The company reported a robust cash position and is advancing its clinical programs, including the pivotal prog", "url": "https://www.investing.com/news/company-news/trevi-therapeutics-stock-hits-alltime-high-at-1933-usd-93CH-4779710", "source_name": "Investing.com", "published_at": "2026-07-08T10:09:37", "published_display": "08 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Trevi Therapeutics, Inc. \u2013 NASDAQ:TRVI", "summary": "This page from TradingView provides financial information for Trevi Therapeutics, Inc. (NASDAQ: TRVI), specifically focusing on its price to sales forward metric. The content indicates the market status (closed) and the availability of various financial tools and data for the com", "url": "https://www.tradingview.com/symbols/NASDAQ-TRVI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T09:10:02", "published_display": "08 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Trevi Therapeutics (TRVI) Fully Priced On Its Russell Index Removal?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Trevi Therapeutics, Inc. \u2013 NASDAQ:TRVI", "summary": "This page provides access to the \"Price to book forward\" financial metric for Trevi Therapeutics, Inc. (NASDAQ: TRVI). It serves as a financial data portal within a larger trading platform, allowing users to view specific financial indicators for the biotechnology company.", "url": "https://www.tradingview.com/symbols/NASDAQ-TRVI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T04:44:49", "published_display": "08 Jul 2026 04:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Trevi Therapeutics, Inc. \u2013 BOATS:TRVI", "summary": "This article provides a financial snapshot for Trevi Therapeutics, Inc. (TRVI) on the Blue Ocean Alternative Trade System (BOATS). It specifically mentions the \"Price to earnings forward\" metric, along with general financial and market data availability. The content primarily foc", "url": "https://www.tradingview.com/symbols/BOATS-TRVI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T03:44:49", "published_display": "08 Jul 2026 03:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics stock hits all-time high at 19.33 USD By Investing.com", "summary": "Trevi Therapeutics (TRVI) stock reached an all-time high of $19.33, reflecting a 226.05% increase over the past year. The company reported strong Q1 2026 earnings with a pro forma cash balance of $334 million and plans to initiate a pivotal program for Haduvio in IPF-CC, with dat", "url": "https://ng.investing.com/news/stock-market-news/trevi-therapeutics-stock-hits-alltime-high-at-1933-usd-93CH-2589452", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T22:10:03", "published_display": "07 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Trevi\u2019s Multi\u2011Index Russell Exit Reshape How Haduvio Drives the Trevi Therapeutics (TRVI) Story?", "summary": "Trevi Therapeutics (TRVI) was delisted from several Russell indices in late June 2026, which could impact its institutional ownership and trading volume. This event, however, does not fundamentally change the Haduvio development narrative, though it highlights the company's relia", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/should-trevis-multiindex-russell-exit-reshape-how-haduvio-dr", "source_name": "Simply Wall Street", "published_at": "2026-07-06T01:11:44", "published_display": "06 Jul 2026 01:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000E Growth Benchmark", "summary": "Trevi Therapeutics, Inc. (NasdaqGM: TRVI) has been removed from the Russell 3000E Growth Benchmark. The company, a clinical-stage biopharmaceutical firm, is focused on developing Haduvio (oral nalbuphine ER) for conditions like chronic cough in IPF patients and refractory chronic", "url": "https://www.marketscreener.com/news/trevi-therapeutics-inc-nasdaqgm-trvi-dropped-from-russell-3000e-growth-benchmark-ce7f5fdedc80f026", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T07:09:06", "published_display": "30 Jun 2026 07:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000E Index", "summary": "Trevi Therapeutics, Inc. (NasdaqGM: TRVI) has been removed from the Russell 3000E Index as of June 29, 2026. This publicly traded biopharmaceutical company focuses on developing Haduvio (oral nalbuphine ER) for chronic cough and pruritus treatments. The article also provides rece", "url": "https://www.marketscreener.com/news/trevi-therapeutics-inc-nasdaqgm-trvi-dropped-from-russell-3000e-index-ce7f5fdeda8dfe23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:50:00", "published_display": "29 Jun 2026 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics, Inc.(NasdaqGM:TRVI) dropped from Russell Microcap Index", "summary": "Trevi Therapeutics, Inc. (TRVI) has been removed from the Russell Microcap Index, following an earlier removal from the Russell 3000E Index. The clinical-stage biopharmaceutical company, which is developing Haduvio for chronic cough and pruritus, has also recently seen lock-up ag", "url": "https://www.marketscreener.com/news/trevi-therapeutics-inc-nasdaqgm-trvi-dropped-from-russell-microcap-index-ce7f5fdeda80f027", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:33:03", "published_display": "29 Jun 2026 05:33", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics stock hits all-time high at 18.17 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNOEJhbC1ubEtVcXhfcERHMnNoQzRGT1hFQnZ6MDJZVWJMOVJMb2FUalJRd3BmMHJOMjU0VjBNM2ZvNlZpVFRvT2d3bjQ2bEVFbHF5VTViUFN5MFJrMVVBem95bGdET2hvZW5EcE5reW1XdXJFRm8xaXVvM1pSQWxTbnl6VWNHMzg2UUJBNkRvUFVmcFFfbi1NZlFQMUZUaTEwZUNxemd3U0tucWx2WkptaQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics, Inc. Actuals & Estimates (NASDAQ:TRVI)", "summary": "This article provides an overview of Trevi Therapeutics, Inc. (NASDAQ:TRVI) stock, including its current price, historical performance, and analyst forecasts. It details financial metrics, earnings estimates, market capitalization, and volatility, along with information on future", "url": "https://www.tradingview.com/symbols/NASDAQ-TRVI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:41:20", "published_display": "26 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRVI Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Trevi Therapeutics, Inc. (TRVI) stock, based on analyst opinions. It details the current stock performance, historical highs and lows, market capitalization, and financial information such as earnings and revenue, along with a", "url": "https://www.tradingview.com/symbols/NASDAQ-TRVI/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:39:30", "published_display": "25 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Announces Upcoming June and July Event Schedule", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/trevi-therapeutics-announces-upcoming-june-113000360.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T11:30:00+00:00", "published_display": "17 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics leaders head to BIO, Boston and London events", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOTURYNW4tQ0JDRXoxWkVuNmlPd1FydEIwaDl0OU5IUzBiUmFqY1JydlhBZVhvSWxsajZHZFB2QU5acW9ZOFNXLXlobzltcGMwV1RLZUFueEI0YXl6Vnc0VzVHalBxVnU3WWFIeDhtX1BRdDJOTFpDNlg1dVpJVmE1eDJ5cWRLR0lyTDVuWEY0WV9qQTNIV3JWWkgtMmlwd1BSRmY4bkRrUjNfRHN3ajMxNDF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.", "summary": "", "url": "https://finance.yahoo.com/m/bd85b2a1-c876-3214-a365-c59a9e29638d/trevi-therapeutics-is-up.html", "source_name": "Motley Fool", "published_at": "2026-06-03T14:04:22+00:00", "published_display": "03 Jun 2026 14:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030", "summary": "", "url": "https://finance.yahoo.com/m/2ac52eeb-1904-3d74-9749-a9049c00d266/trevi-therapeutics-maps.html", "source_name": "MarketBeat", "published_at": "2026-05-09T09:05:20+00:00", "published_display": "09 May 2026 09:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/96abae3c-3b20-35a2-af11-76c8fab564aa/trevi-therapeutics%2C-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-06T16:58:09+00:00", "published_display": "06 May 2026 16:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Adjusts Trevi Therapeutics Price Target to $21 From $16, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/b-riley-adjusts-trevi-therapeutics-120657648.html", "source_name": "MT Newswires", "published_at": "2026-05-06T12:06:57+00:00", "published_display": "06 May 2026 12:06", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Q1 Loss Unchanged", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/trevi-therapeutics-q1-loss-unchanged-082948625.html", "source_name": "MT Newswires", "published_at": "2026-05-06T08:29:48+00:00", "published_display": "06 May 2026 08:29", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNZmJoZVhpVGw1cUU5bmxFS240ZlFFNTNYMXJzTEpnclVYRFJmVjRmWmZMN21wWXlmbkdXckUzcnFPNFdHb3drcHREclZ2c0RkT1lYZ2NFMW40cmZ5TFBxY3dadW1sLWZBU0prd3pIWU5KV2xwdGU1NXBmbDNMWlhjRkVWRGl5MFJPQmFBdV9MZFVWV0VmQzNYTGZicjJFSTQ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxOTUVaZkhrYXNoOFZUc1dWUFpRQ3JReUcxM0tCTTU1YWdSbXR1QmtwOFlGYkFvOUVWSFE3dGZISjZ1bmdKYTJRQW5FLXRFSTBoSnJvLVAtRENKM0dLUXNUcTJwbVI1dFMyLWhwdlZPbjhmX2FVUjd1WUp4QnNjWDlYSl83Qng0d29seTVoZzNsRlJCOUpYeXIyS05VZGJqdHo3c0E5bmJnODF4NDlVUnp4ai11NW0wZWdDc3lHR2dIeG9ENXkyVzF1bmFhdmVWS01TTTV0UHNEOHBqUThRT1k3d0tWZDUxV0d4SUNBS25hbEdJLWZEOGYzcw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "New Haven\u2019s Trevi Therapeutics plans $150M stock offering to fund late-stage drug trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPZUxDVUZfbXRHOTNrYVNyWGppaS14NnZfYXRGOWpzYms3WmhIZ2RuZU41N3I0MkRzWFYtLUY2MGVwU2k4YzB4ZzM3QWFKVWZYemh3cmtuSmJwUDFfRGpQcm5lckJ3SzcwbWhtU2RaSDBSa0F2Q0plLTduNDVBcEI2Sk9PaTNkTVJpR0lWNFN4NllWRzBBcGJjQjVyaXdVcmFVOXA4M0J4WGEzczNuUklDUC1MR1ZxZW4wbDlvN3ltTl91dw?oc=5", "source_name": "Hartford Business Journal", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi seeks $150M from investors, with option for $22.5M more", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPcUQ2MElXUVJzcnQyalZtVWFBWE9KLXVBQktWbjlfT2gxWDZPTWowUmYtSF8waU9GU2UtdGdUYU5LRXk0TV9KTG1wejdvQzJzVHA1LVk2RjJaZjctZFgxQ0tOSGNoanhXbmVmWWR4Q2ZWakF5aXZlX0NBODNBTlBzUDlya3RoY0tBSWNwRGFNTlVxaFlwbXNTTUFiWWd4aDAyTVNBNURfb20tNW5aX3RFNk1jN1g4ZlJSckE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOaWg2SVBHSzJJQWQ2REJfM1NKZVd5TF9ESXd6ZDIzRWFqWUV0LW5KanZPMGIxdVVWanRrUXJlNzVKcmZGYi0zRXlyVEZvUUlPWHhfbXJqTHEtUm9LTDI1NXRnNW1WcmxQaVVWTkhOZ1pGY1FTdkF2UWxsVG9sR3VsZ2pqT1kxaElhRWdPOERDUF9xdlRVM1pma3pGM0Y5QlJfakFzRjdybjJBRUU?oc=5", "source_name": "Market source", "published_at": "2026-04-05T07:00:00+00:00", "published_display": "05 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target", "summary": "BMO Capital has initiated coverage on Trevi Therapeutics (TRVI) with an Outperform rating and set a price target of $36. This announcement follows B. Riley's recent adjustment of Trevi Therapeutics' price target to $31 from $21, maintaining a Buy rating. Trevi Therapeutics is a c", "url": "https://www.marketscreener.com/news/bmo-capital-initiates-trevi-therapeutics-at-outperform-with-36-price-target-ce7f51d8d98ef02c", "source_name": "marketscreener.com", "published_at": "2026-07-21T11:12:05", "published_display": "21 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BMO initiates Trevi Therapeutics stock at Outperform, $36 target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOZkdKYkhON2phZWtKVllfcVJJbjl6dEk1dE5UWmNCdUR4YWhKTnpsbFJINm1YZkMySE4xRTktc3gtM1NHWEthVUNfUlM4TUJZdGgtZlR4QVZCU2MyZWhDTE1VX1V1R1NHenJFQmNIcjlIb04ta3RqRF8zcHktT3pqckk5Z3FyYkRPRVZJYW42cHBJZmtkbUNDS1lfbllOY2FDMFZCRWJlYjFWS0FfZTNnMFJuQlU2a1FYMlIwTnZMaWYzejlkNFBKTmlB?oc=5", "source_name": "Investing.com", "published_at": "2026-07-20T21:48:00+00:00", "published_display": "20 Jul 2026 21:48", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1% - Here's Why", "summary": "Trevi Therapeutics (NASDAQ:TRVI) saw its shares drop 5.1% on Monday, trading as low as $18.03 with below-average volume, following a previous close of $19.07. This decline occurred despite several analysts recently raising price targets and maintaining a \"Moderate Buy\" consensus ", "url": "https://www.marketbeat.com/instant-alerts/trevi-therapeutics-nasdaqtrvi-shares-down-51-heres-why-2026-07-20/", "source_name": "MarketBeat", "published_at": "2026-07-20T18:09:43", "published_display": "20 Jul 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Financial Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNUjBtTzJBbENaWi0zdFRoSWpET0JWZFNrSC1NQlU1Wi1BMHRoWDljLWNjdG1wVkhTdGo0OWd4QkQ4WW9IQmpMd3FjbkQzZmNmU3hwSjI2akw0ZE9oRXlyYVBtc2V0N1JweHlkbU5ZVmFQVkNnZWhEQXNsMUJDbWtzTjZTOUxWczBqM2Q1R0w4MjJpb0tEM1VTb3RJUnlLSWcyOFVaU1Iwcm5YVE9pQ0doem9fZm9KaHA4ZzZyZ0RuWXFaeTdweF9wbnBvemh5LWd4eDNYM0lHdVVNQQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-20T13:50:48+00:00", "published_display": "20 Jul 2026 13:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Adjusts Trevi Therapeutics Price Target to $31 From $21, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/b-riley-adjusts-trevi-therapeutics-120905218.html", "source_name": "MT Newswires", "published_at": "2026-07-20T12:09:05+00:00", "published_display": "20 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOb2tfRFpCSXdTR2ZhUUhRcGxDRllWY1RrS0tsMUNTMllXUXozOXc5NkdpNkxhaTdXVlctVFNJMkFlZXFabTlYUXpYUjg3WHhoQ2hyeGZfYi1xZmhBbkRDSDI0d09FbkxLQ0xyWGdiQXBnTHV3eG00dkYxRmwyMDRPbXZ6eUZ3cW5QT3dqVjRYX1lET2ViZm5iZlNMdllZUlB4TUhGMUhaLVk2cEJ0SmxnUUZMWG9QWVdLcjB6UWRTdVZ0ZjFqOGZuX3U0cmZmZnFNbTdFdUkxTmhRREpGU3dfdGFUNVQxMGZCM1Fma0FfOVFQUFFFTUtXdXc4a2xfcTQycEduZDVOenZJMUtQLXpJQnlCOE0tQ3VLMGlGdWNfcUxrQUk5cklRaXlUR2U?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-20T12:08:00+00:00", "published_display": "20 Jul 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics stock price target raised to $24 by H.C. Wainwright", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPdmFSeG9yb09OQmFSZmJpMEIzUmUteGZsVUN6Rjh1LXpLaWU0ZldnRU53X0p2ZDJtOENkaGQ4bnNvVHI4SXJLSEs3MmZXNVB0QU54WmlnZXQyVGtFNmliNTg4bDUwZFA4YmllLUdpTngybVg3WDlvUkdBb0ZMTVNiU3pYTUYzX2FQb3RBWERxYk9jYXRRbHR4N2tiV2s4aDd1MHluekhxaTdCakpMM1p2azNiXzFqM0RuTGFVTDluM1V6SHFvbXc?oc=5", "source_name": "Investing.com", "published_at": "2026-07-20T11:40:57+00:00", "published_display": "20 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price", "summary": "HC Wainwright has raised its price target for Trevi Therapeutics (NASDAQ:TRVI) to $24 from $21, maintaining a buy rating and suggesting a potential upside of 25.85%. Despite a recent quarterly EPS miss, other analysts also hold a generally positive outlook, contributing to a cons", "url": "https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-positive-forecast-for-trevi-therapeutics-nasdaqtrvi-stock-price-2026-07-20/", "source_name": "MarketBeat", "published_at": "2026-07-20T11:41:30", "published_display": "20 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "_TRVI Surges As Trevi Therapeutics Draws Fresh Bullish Momentum", "summary": "Trevi Therapeutics Inc. (TRVI) stock surged over 11% following optimistic investor response to clinical progress and a non-deal roadshow. Despite being a development-stage biotech with negative profitability and cash burn, the company boasts a strong balance sheet with substantia", "url": "https://www.timothysykes.com/news/trevitherapeuticsinc-trvi-news-2026_07_19-2/", "source_name": "www.timothysykes.com", "published_at": "2026-07-19T14:07:00", "published_display": "19 Jul 2026 14:07", "sentiment": "positive", "sentiment_pct": 75, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRVI Surges As Trevi Therapeutics Draws Aggressive Buyers", "summary": "Trevi Therapeutics (TRVI) stock surged by 11.6% due to strong investor optimism driven by promising clinical progress and aggressive accumulation by traders. Despite being a clinical-stage biotech with no product revenue and negative fundamentals, TRVI boasts exceptional liquidit", "url": "https://timothysykes.com/news/trevitherapeuticsinc-trvi-news-2026_07_19/", "source_name": "timothysykes.com", "published_at": "2026-07-19T10:08:00", "published_display": "19 Jul 2026 10:08", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics (TRVI) Is Up 6.9% After Haduvio Cough Data And New ILD Trial Plan - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-19T08:31:28+00:00", "published_display": "19 Jul 2026 08:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Stock Jumps As Momentum Traders Pile In", "summary": "Trevi Therapeutics Inc. (TRVI) stock has experienced an 11.6% jump, driven by positive drug trial news and aggressive buying interest from momentum traders. Despite being a clinical-stage biotech with negative profitability, the company maintains strong liquidity with $172M in ca", "url": "https://timothysykes.com/news/trevitherapeuticsinc-trvi-news-2026_07_18-2/", "source_name": "timothysykes.com", "published_at": "2026-07-18T15:09:54", "published_display": "18 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRVI Jumps As Trevi Therapeutics Extends Rally On Heavy Interest", "summary": "Trevi Therapeutics (TRVI) stock experienced an 11.6% surge following promising clinical data, generating significant investor and trading interest. The company is set to meet institutional investors in London, contributing to positive sentiment. Despite being a clinical-stage bio", "url": "https://stockstotrade.com/news/trevitherapeuticsinc-trvi-news-2026_07_18-2/", "source_name": "StocksToTrade", "published_at": "2026-07-18T11:38:00", "published_display": "18 Jul 2026 11:38", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRVI Jumps As Trevi Therapeutics Extends Bullish Run", "summary": "Trevi Therapeutics Inc. (TRVI) stock has jumped by 11.6% due to optimism over its latest clinical trial developments and a Cantor Fitzgerald-hosted non-deal roadshow in London. Despite strong liquidity and no debt, the company is pre-revenue with negative returns and significant ", "url": "https://timothysykes.com/news/trevitherapeuticsinc-trvi-news-2026_07_18/", "source_name": "timothysykes.com", "published_at": "2026-07-18T10:08:00", "published_display": "18 Jul 2026 10:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year High - Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOT0J0aTY0UXcteDdWTU1DUHdoZzNzbzlUbFlwRDVKUVRZc2Y3SkV2dmRId0FMNmxvbFIwUUs2alNVX2g2di1tVVJpRXBiLUgtQW16bVhKTTNYQ3RkeHBwZ19DWVVqQ1dhb2w5TlNwV1ViV1k5ZnZYbHZMSjlYVERSdGRZTW9pdGtUMWpMRUxfZnRoMS1pcU1vbmo0Rng0RVNoTl9Rb0tFRjZDVkFsS0VGMU0yMjg?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-18T08:34:57+00:00", "published_display": "18 Jul 2026 08:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Trevi Therapeutics (TRVI) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxObmxkaWs5NFFka183TkNaa1VUdHFaZEhjVE5jbzliRjN0SHk5eDdJRTE0Ql92aVFjQmx3eEVNUm1OOXVRa1NBSmNHVGFTSlFacXZILTVnbVpsZnZiOTlkdmdLU1F6TmV0aGhleWFSaUNyLW9rRDB0N2Z2N3JlNzdMU045TVpDYVM2T3d6NQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T18:37:00+00:00", "published_display": "17 Jul 2026 18:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics (TRVI) Stock May Be Overvalued Despite Its 5 Year Surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNQ0tacHpuVUVndE0zZTNzN2xteW4xOUdtZW0tNExScFVNWVdIMGZucXU2c0dQNGpFT1JOclBwN1ZXOERpbHdXa1NpVXdGTEUwU1p2dkI2bHpRV3dXTDBOd0xIbWtkSlY5eXR5enpYOUNYX2o2ZGp2NVpGeGFJcGNuRkVDdzJlNkpjSlNMbTJFVUl5cG43dVZNc3FkM2M4dTZ5Qzl1emltT3NsVEZXVk1DYTNZYzduejZrZkVyYlhheE10clo1WjU2VUhrTjdpazZaWk5lUERlRlJUcXFUdXVlSGN0Nm1TQdIB6wFBVV95cUxNMnZORVRuUnFMX2JFRVl4QnN6dE9OZW9JT2ZJc2Q5TWhjQ01QVWdyM0NOYlhoWHRuMTVOak55ckQ2MTVZaGYxYzBUczkwSzBqemx4dFFjS0Y1NUQxbEJOZ1VqZVF2UkdrX0pLV1hyRXFUTlZSMFRTeHFxWG9UOEhNUWFvbXdrSVNwR01WQTdmYk45SWVNV1BoSXQzOVQxa1MzQ01hSmM0Ty1HNE15VUViYWFVUE1wOGVNbV94Z1lLa2VHb3RnQkdFVFRIRlJCajZLcmhlUFBpODNObHJueEVwT2tKLTJDakNwV1JV?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-17T18:35:32+00:00", "published_display": "17 Jul 2026 18:35", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market", "summary": "Trevi Therapeutics (TRVI) saw its share prices rise by 9.85% after its CEO and Chief Development Officer presented strong clinical trial results for Haduvio, their treatment candidate for chronic cough, at a European conference. Haduvio, an extended-release formulation of nalbuph", "url": "https://finance.yahoo.com/healthcare/articles/trevi-therapeutics-trvi-soars-haduvio-022042519.html", "source_name": "Market source", "published_at": "2026-07-17T19:20:00", "published_display": "17 Jul 2026 19:20", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi climbs as GSK drops chronic cough therapy (TRVI:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQdUo3eHpCV3dJZl9jZEhBODloS3g5YTNZZERWMDE1V1Jhck12em1VMjVFZ2FVSUxHd3NrNUV0allNckhnejdyOV9kNWZ0cXZaUXE0V0tialc0Z0djelpNUkVDaWlEcERRdDdkdEdXYnRYRE81T0t5Qy16d1U0aUJfWVNTODBTdmxSM3c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-17T18:04:33+00:00", "published_display": "17 Jul 2026 18:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRVI Stock Firms Up As Haduvio Story Hits Center Stage", "summary": "Trevi Therapeutics Inc. (TRVI) stock is showing a strong upturn, driven by optimism surrounding its Haduvio clinical development and an aggressive outreach campaign. Management is engaging in a London non-deal roadshow hosted by Cantor Fitzgerald and participating in multiple ind", "url": "https://stockstotrade.com/news/trevi-therapeutics-inc-trvi-news-2026_07_17/", "source_name": "StocksToTrade", "published_at": "2026-07-17T17:40:36", "published_display": "17 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading Volume - Should You Buy?", "summary": "Trevi Therapeutics (NASDAQ:TRVI) experienced a significant surge in trading volume and stock price, with shares jumping to $20.12 on Friday. Analysts maintain a generally positive outlook, reiterating \"buy\" ratings and setting an average price target of $22.67, despite the compan", "url": "https://www.marketbeat.com/instant-alerts/trevi-therapeutics-nasdaqtrvi-sees-strong-trading-volume-should-you-buy-2026-07-17/", "source_name": "MarketBeat", "published_at": "2026-07-17T16:40:35", "published_display": "17 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Traders Buy Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI)", "summary": "Trevi Therapeutics (NASDAQ:TRVI) experienced a significant surge in call option trading, with 13,996 call options bought on Wednesday, a 1,258% increase from the typical volume. This occurred despite a 0.43% share price drop to $17.48. Analysts maintain a \"Buy\" consensus rating w", "url": "https://www.marketbeat.com/instant-alerts/stock-traders-buy-large-volume-of-trevi-therapeutics-call-options-nasdaqtrvi-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T17:48:44", "published_display": "15 Jul 2026 17:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candriam S.C.A. Purchases Shares of 773,620 Trevi Therapeutics, Inc. $TRVI", "summary": "Candriam S.C.A. acquired a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the first quarter, purchasing 773,620 shares valued at approximately $9.23 million. This investment represents about 0.60% of Trevi Therapeutics' total ownership. Other institutional investor", "url": "https://www.marketbeat.com/instant-alerts/filing-candriam-sca-purchases-shares-of-773620-trevi-therapeutics-inc-trvi-2026-07-13/", "source_name": "MarketBeat", "published_at": "2026-07-13T08:11:12", "published_display": "13 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SG Americas Securities LLC Decreases Stock Position in Trevi Therapeutics, Inc. $TRVI", "summary": "SG Americas Securities LLC significantly reduced its stake in Trevi Therapeutics (NASDAQ:TRVI) by 77.5% in the first quarter, selling 96,511 shares and leaving them with 28,051 shares. Despite this reduction, institutional investors collectively hold a strong position, with 95.76", "url": "https://www.marketbeat.com/instant-alerts/filing-sg-americas-securities-llc-decreases-stock-position-in-trevi-therapeutics-inc-trvi-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T09:09:37", "published_display": "10 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRVi stock stays tied to Trevi Therapeutics' clinical outlook", "summary": "Trevi Therapeutics (TRVI) stock performance is predominantly influenced by its clinical pipeline progress, especially its oral therapies for chronic cough and fibrosis-related conditions. The company's valuation relies heavily on successful study readouts and its ability to trans", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/trvi-stock-stays-tied-to-trevi-therapeutics-clinical-outlook/69733563", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T18:17:00", "published_display": "09 Jul 2026 18:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Trevi Therapeutics, Inc. \u2013 NASDAQ:TRVI", "summary": "This article displays information regarding the forward price-to-earnings ratio for Trevi Therapeutics, Inc. (NASDAQ: TRVI). It serves as a financial data point within a trading platform interface for investors and analysts, without providing further analysis or discussion. The a", "url": "https://www.tradingview.com/symbols/NASDAQ-TRVI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T23:41:58", "published_display": "08 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics stock hits all-time high at 19.33 USD", "summary": "Trevi Therapeutics (TRVI) stock recently reached an all-time high of $19.33, reflecting a significant 226.05% increase over the past year and strong investor confidence. The company reported a robust cash position and is advancing its clinical programs, including the pivotal prog", "url": "https://www.investing.com/news/company-news/trevi-therapeutics-stock-hits-alltime-high-at-1933-usd-93CH-4779710", "source_name": "Investing.com", "published_at": "2026-07-08T10:09:37", "published_display": "08 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Trevi Therapeutics, Inc. \u2013 NASDAQ:TRVI", "summary": "This page from TradingView provides financial information for Trevi Therapeutics, Inc. (NASDAQ: TRVI), specifically focusing on its price to sales forward metric. The content indicates the market status (closed) and the availability of various financial tools and data for the com", "url": "https://www.tradingview.com/symbols/NASDAQ-TRVI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T09:10:02", "published_display": "08 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Trevi Therapeutics (TRVI) Fully Priced On Its Russell Index Removal?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Trevi Therapeutics, Inc. \u2013 NASDAQ:TRVI", "summary": "This page provides access to the \"Price to book forward\" financial metric for Trevi Therapeutics, Inc. (NASDAQ: TRVI). It serves as a financial data portal within a larger trading platform, allowing users to view specific financial indicators for the biotechnology company.", "url": "https://www.tradingview.com/symbols/NASDAQ-TRVI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T04:44:49", "published_display": "08 Jul 2026 04:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Trevi Therapeutics, Inc. \u2013 BOATS:TRVI", "summary": "This article provides a financial snapshot for Trevi Therapeutics, Inc. (TRVI) on the Blue Ocean Alternative Trade System (BOATS). It specifically mentions the \"Price to earnings forward\" metric, along with general financial and market data availability. The content primarily foc", "url": "https://www.tradingview.com/symbols/BOATS-TRVI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T03:44:49", "published_display": "08 Jul 2026 03:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics stock hits all-time high at 19.33 USD By Investing.com", "summary": "Trevi Therapeutics (TRVI) stock reached an all-time high of $19.33, reflecting a 226.05% increase over the past year. The company reported strong Q1 2026 earnings with a pro forma cash balance of $334 million and plans to initiate a pivotal program for Haduvio in IPF-CC, with dat", "url": "https://ng.investing.com/news/stock-market-news/trevi-therapeutics-stock-hits-alltime-high-at-1933-usd-93CH-2589452", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T22:10:03", "published_display": "07 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Trevi\u2019s Multi\u2011Index Russell Exit Reshape How Haduvio Drives the Trevi Therapeutics (TRVI) Story?", "summary": "Trevi Therapeutics (TRVI) was delisted from several Russell indices in late June 2026, which could impact its institutional ownership and trading volume. This event, however, does not fundamentally change the Haduvio development narrative, though it highlights the company's relia", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/should-trevis-multiindex-russell-exit-reshape-how-haduvio-dr", "source_name": "Simply Wall Street", "published_at": "2026-07-06T01:11:44", "published_display": "06 Jul 2026 01:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000E Growth Benchmark", "summary": "Trevi Therapeutics, Inc. (NasdaqGM: TRVI) has been removed from the Russell 3000E Growth Benchmark. The company, a clinical-stage biopharmaceutical firm, is focused on developing Haduvio (oral nalbuphine ER) for conditions like chronic cough in IPF patients and refractory chronic", "url": "https://www.marketscreener.com/news/trevi-therapeutics-inc-nasdaqgm-trvi-dropped-from-russell-3000e-growth-benchmark-ce7f5fdedc80f026", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T07:09:06", "published_display": "30 Jun 2026 07:09", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000E Index", "summary": "Trevi Therapeutics, Inc. (NasdaqGM: TRVI) has been removed from the Russell 3000E Index as of June 29, 2026. This publicly traded biopharmaceutical company focuses on developing Haduvio (oral nalbuphine ER) for chronic cough and pruritus treatments. The article also provides rece", "url": "https://www.marketscreener.com/news/trevi-therapeutics-inc-nasdaqgm-trvi-dropped-from-russell-3000e-index-ce7f5fdeda8dfe23", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:50:00", "published_display": "29 Jun 2026 12:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics, Inc.(NasdaqGM:TRVI) dropped from Russell Microcap Index", "summary": "Trevi Therapeutics, Inc. (TRVI) has been removed from the Russell Microcap Index, following an earlier removal from the Russell 3000E Index. The clinical-stage biopharmaceutical company, which is developing Haduvio for chronic cough and pruritus, has also recently seen lock-up ag", "url": "https://www.marketscreener.com/news/trevi-therapeutics-inc-nasdaqgm-trvi-dropped-from-russell-microcap-index-ce7f5fdeda80f027", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:33:03", "published_display": "29 Jun 2026 05:33", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics stock hits all-time high at 18.17 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNOEJhbC1ubEtVcXhfcERHMnNoQzRGT1hFQnZ6MDJZVWJMOVJMb2FUalJRd3BmMHJOMjU0VjBNM2ZvNlZpVFRvT2d3bjQ2bEVFbHF5VTViUFN5MFJrMVVBem95bGdET2hvZW5EcE5reW1XdXJFRm8xaXVvM1pSQWxTbnl6VWNHMzg2UUJBNkRvUFVmcFFfbi1NZlFQMUZUaTEwZUNxemd3U0tucWx2WkptaQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics, Inc. Actuals & Estimates (NASDAQ:TRVI)", "summary": "This article provides an overview of Trevi Therapeutics, Inc. (NASDAQ:TRVI) stock, including its current price, historical performance, and analyst forecasts. It details financial metrics, earnings estimates, market capitalization, and volatility, along with information on future", "url": "https://www.tradingview.com/symbols/NASDAQ-TRVI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:41:20", "published_display": "26 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TRVI Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Trevi Therapeutics, Inc. (TRVI) stock, based on analyst opinions. It details the current stock performance, historical highs and lows, market capitalization, and financial information such as earnings and revenue, along with a", "url": "https://www.tradingview.com/symbols/NASDAQ-TRVI/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:39:30", "published_display": "25 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Announces Upcoming June and July Event Schedule", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/trevi-therapeutics-announces-upcoming-june-113000360.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T11:30:00+00:00", "published_display": "17 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics leaders head to BIO, Boston and London events", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOTURYNW4tQ0JDRXoxWkVuNmlPd1FydEIwaDl0OU5IUzBiUmFqY1JydlhBZVhvSWxsajZHZFB2QU5acW9ZOFNXLXlobzltcGMwV1RLZUFueEI0YXl6Vnc0VzVHalBxVnU3WWFIeDhtX1BRdDJOTFpDNlg1dVpJVmE1eDJ5cWRLR0lyTDVuWEY0WV9qQTNIV3JWWkgtMmlwd1BSRmY4bkRrUjNfRHN3ajMxNDF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.", "summary": "", "url": "https://finance.yahoo.com/m/bd85b2a1-c876-3214-a365-c59a9e29638d/trevi-therapeutics-is-up.html", "source_name": "Motley Fool", "published_at": "2026-06-03T14:04:22+00:00", "published_display": "03 Jun 2026 14:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030", "summary": "", "url": "https://finance.yahoo.com/m/2ac52eeb-1904-3d74-9749-a9049c00d266/trevi-therapeutics-maps.html", "source_name": "MarketBeat", "published_at": "2026-05-09T09:05:20+00:00", "published_display": "09 May 2026 09:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/96abae3c-3b20-35a2-af11-76c8fab564aa/trevi-therapeutics%2C-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-06T16:58:09+00:00", "published_display": "06 May 2026 16:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Riley Adjusts Trevi Therapeutics Price Target to $21 From $16, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/b-riley-adjusts-trevi-therapeutics-120657648.html", "source_name": "MT Newswires", "published_at": "2026-05-06T12:06:57+00:00", "published_display": "06 May 2026 12:06", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Q1 Loss Unchanged", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/trevi-therapeutics-q1-loss-unchanged-082948625.html", "source_name": "MT Newswires", "published_at": "2026-05-06T08:29:48+00:00", "published_display": "06 May 2026 08:29", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNZmJoZVhpVGw1cUU5bmxFS240ZlFFNTNYMXJzTEpnclVYRFJmVjRmWmZMN21wWXlmbkdXckUzcnFPNFdHb3drcHREclZ2c0RkT1lYZ2NFMW40cmZ5TFBxY3dadW1sLWZBU0prd3pIWU5KV2xwdGU1NXBmbDNMWlhjRkVWRGl5MFJPQmFBdV9MZFVWV0VmQzNYTGZicjJFSTQ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxOTUVaZkhrYXNoOFZUc1dWUFpRQ3JReUcxM0tCTTU1YWdSbXR1QmtwOFlGYkFvOUVWSFE3dGZISjZ1bmdKYTJRQW5FLXRFSTBoSnJvLVAtRENKM0dLUXNUcTJwbVI1dFMyLWhwdlZPbjhmX2FVUjd1WUp4QnNjWDlYSl83Qng0d29seTVoZzNsRlJCOUpYeXIyS05VZGJqdHo3c0E5bmJnODF4NDlVUnp4ai11NW0wZWdDc3lHR2dIeG9ENXkyVzF1bmFhdmVWS01TTTV0UHNEOHBqUThRT1k3d0tWZDUxV0d4SUNBS25hbEdJLWZEOGYzcw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Haven\u2019s Trevi Therapeutics plans $150M stock offering to fund late-stage drug trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPZUxDVUZfbXRHOTNrYVNyWGppaS14NnZfYXRGOWpzYms3WmhIZ2RuZU41N3I0MkRzWFYtLUY2MGVwU2k4YzB4ZzM3QWFKVWZYemh3cmtuSmJwUDFfRGpQcm5lckJ3SzcwbWhtU2RaSDBSa0F2Q0plLTduNDVBcEI2Sk9PaTNkTVJpR0lWNFN4NllWRzBBcGJjQjVyaXdVcmFVOXA4M0J4WGEzczNuUklDUC1MR1ZxZW4wbDlvN3ltTl91dw?oc=5", "source_name": "Hartford Business Journal", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trevi seeks $150M from investors, with option for $22.5M more", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPcUQ2MElXUVJzcnQyalZtVWFBWE9KLXVBQktWbjlfT2gxWDZPTWowUmYtSF8waU9GU2UtdGdUYU5LRXk0TV9KTG1wejdvQzJzVHA1LVk2RjJaZjctZFgxQ0tOSGNoanhXbmVmWWR4Q2ZWakF5aXZlX0NBODNBTlBzUDlya3RoY0tBSWNwRGFNTlVxaFlwbXNTTUFiWWd4aDAyTVNBNURfb20tNW5aX3RFNk1jN1g4ZlJSckE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOaWg2SVBHSzJJQWQ2REJfM1NKZVd5TF9ESXd6ZDIzRWFqWUV0LW5KanZPMGIxdVVWanRrUXJlNzVKcmZGYi0zRXlyVEZvUUlPWHhfbXJqTHEtUm9LTDI1NXRnNW1WcmxQaVVWTkhOZ1pGY1FTdkF2UWxsVG9sR3VsZ2pqT1kxaElhRWdPOERDUF9xdlRVM1pma3pGM0Y5QlJfakFzRjdybjJBRUU?oc=5", "source_name": "Market source", "published_at": "2026-04-05T07:00:00+00:00", "published_display": "05 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 61, "sentiment_summary": {"positive": 22, "negative": 5, "neutral": 34, "score": 58, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 13.55, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 10.31, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "liquidity", "label": "Balance sheet", "weight": 3.3, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 2.2, "count": 4}], "positive_events": 22, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 19.07, "latest_week": "2026-07-17", "one_week_move": 6.9, "four_week_move": 10.8, "twelve_week_move": 32.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.678918, "market_dynamics_buy_signal": false, "relative_strength": 46.604828, "fair_value_gap": 207.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.8636, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.9% over one week, +10.8% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "MarketBeat", "count": 9}, {"label": "Market source", "count": 9}, {"label": "TradingView", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "timothysykes.com", "count": 3}, {"label": "www.marketscreener.com", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 21}, {"label": "Analyst action", "count": 6}, {"label": "Balance sheet", "count": 6}, {"label": "Guidance", "count": 4}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.9% over one week, +10.8% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target"}], "updated_at": "2026-07-22T05:22:36.112456+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}